Skip to main content
icon for Qui Trump annoncera-t-il comme prochain commissaire de la FDA ?

Qui Trump annoncera-t-il comme prochain commissaire de la FDA ?

icon for Qui Trump annoncera-t-il comme prochain commissaire de la FDA ?

Qui Trump annoncera-t-il comme prochain commissaire de la FDA ?

Kyle Diamantas 54%

No announcement by December 31 14.0%

Stephen Hahn 4%

Brett Giroir 3.9%

Polymarket
NOUVEAU

Kyle Diamantas 54%

No announcement by December 31 14.0%

Stephen Hahn 4%

Brett Giroir 3.9%

Polymarket
NOUVEAU

Kyle Diamantas

$1,525 Vol.

54%

Stephen Hahn

$976 Vol.

4%

Brett Giroir

$1,510 Vol.

4%

Grace Graham

$1,893 Vol.

3%

Sara Brenner

$849 Vol.

3%

No announcement by December 31

$533 Vol.

14%

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Following Marty Makary's resignation as FDA commissioner earlier this month, President Trump appointed Kyle Diamantas as acting commissioner. Diamantas, previously the deputy overseeing the agency's food program with longstanding administration ties, now holds the interim role amid Senate confirmation requirements for any permanent successor. This immediate elevation has driven trader consensus toward Diamantas at 53% implied probability, reflecting the practical edge of acting status and White House endorsement in filling the vacancy. The 11.6% probability attached to no announcement by December 31 incorporates potential delays in the confirmation process, while lower odds for figures such as Stephen Hahn and Brett Giroir align with their comparatively limited recent visibility in administration health policy discussions.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$7,286
Date de fin
31 déc. 2026
Marché ouvert
May 12, 2026, 7:59 PM ET
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Following Marty Makary's resignation as FDA commissioner earlier this month, President Trump appointed Kyle Diamantas as acting commissioner. Diamantas, previously the deputy overseeing the agency's food program with longstanding administration ties, now holds the interim role amid Senate confirmation requirements for any permanent successor. This immediate elevation has driven trader consensus toward Diamantas at 53% implied probability, reflecting the practical edge of acting status and White House endorsement in filling the vacancy. The 11.6% probability attached to no announcement by December 31 incorporates potential delays in the confirmation process, while lower odds for figures such as Stephen Hahn and Brett Giroir align with their comparatively limited recent visibility in administration health policy discussions.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$7,286
Date de fin
31 déc. 2026
Marché ouvert
May 12, 2026, 7:59 PM ET
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.

Méfiez-vous des liens externes.

Questions fréquentes

« Qui Trump annoncera-t-il comme prochain commissaire de la FDA ? » est un marché de prédiction sur Polymarket avec 6 résultats possibles où les traders achètent et vendent des parts selon ce qu'ils pensent qu'il se passera. Le résultat en tête actuel est « Kyle Diamantas » à 54%, suivi de « No announcement by December 31 » à 14%. Les prix reflètent des probabilités en temps réel de la communauté. Par exemple, une part cotée à 54¢ implique que le marché attribue collectivement une probabilité de 54% à ce résultat. Ces cotes changent en permanence. Les parts du résultat correct sont échangeables contre $1 chacune lors de la résolution du marché.

« Qui Trump annoncera-t-il comme prochain commissaire de la FDA ? » est un marché nouvellement créé sur Polymarket, lancé le May 13, 2026. En tant que marché récent, c'est votre opportunité d'être parmi les premiers traders à définir les cotes et établir les premiers signaux de prix du marché. Vous pouvez également ajouter cette page à vos favoris pour suivre le volume et l'activité de trading au fil du temps.

Pour trader sur « Qui Trump annoncera-t-il comme prochain commissaire de la FDA ? », parcourez les 6 résultats disponibles sur cette page. Chaque résultat affiche un prix actuel représentant la probabilité implicite du marché. Pour prendre position, sélectionnez le résultat que vous estimez le plus probable, choisissez « Oui » pour trader en sa faveur ou « Non » pour trader contre, entrez votre montant et cliquez sur « Trader ». Si votre résultat choisi est correct lors de la résolution, vos parts « Oui » rapportent $1 chacune. S'il est incorrect, elles rapportent $0. Vous pouvez également vendre vos parts avant la résolution.

Le favori actuel pour « Qui Trump annoncera-t-il comme prochain commissaire de la FDA ? » est « Kyle Diamantas » à 54%, ce qui signifie que le marché attribue une probabilité de 54% à ce résultat. Le résultat le plus proche ensuite est « No announcement by December 31 » à 14%. Ces cotes sont mises à jour en temps réel à mesure que les traders achètent et vendent des parts. Revenez fréquemment ou ajoutez cette page à vos favoris.

Les règles de résolution de « Qui Trump annoncera-t-il comme prochain commissaire de la FDA ? » définissent exactement ce qui doit se produire pour que chaque résultat soit déclaré gagnant, y compris les sources de données officielles utilisées pour déterminer le résultat. Vous pouvez consulter les critères de résolution complets dans la section « Règles » sur cette page au-dessus des commentaires. Nous recommandons de lire attentivement les règles avant de trader, car elles précisent les conditions exactes, les cas particuliers et les sources.